Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Circulation ; 122(11 Suppl): S118-23, 2010 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-20837902

RESUMEN

BACKGROUND: The safety and efficacy of myocardial regeneration using embryonic stem cells are limited by the risk of teratoma and the high rate of cell death. METHODS AND RESULTS: To address these issues, we developed a composite construct made of a sheet of adipose tissue-derived stroma cells and embryonic stem cell-derived cardiac progenitors. Ten Rhesus monkeys underwent a transient coronary artery occlusion followed, 2 weeks later, by the open-chest delivery of the composite cell sheet over the infarcted area or a sham operation. The sheet was made of adipose tissue-derived stroma cells grown from a biopsy of autologous adipose tissue and cultured onto temperature-responsive dishes. Allogeneic Rhesus embryonic stem cells were committed to a cardiac lineage and immunomagnetically sorted to yield SSEA-1(+) cardiac progenitors, which were then deposited onto the cell sheet. Cyclosporine was given for 2 months until the animals were euthanized. Preimplantation studies showed that the SSEA-1(+) progenitors expressed cardiac markers and had lost pluripotency. After 2 months, there was no teratoma in any of the 5 cell-treated monkeys. Analysis of >1500 histological sections showed that the SSEA-1(+) cardiac progenitors had differentiated into cardiomyocytes, as evidenced by immunofluorescence and real-time polymerase chain reaction. There were also a robust engraftment of autologous adipose tissue-derived stroma cells and increased angiogenesis compared with the sham animals. CONCLUSIONS: These data collected in a clinically relevant nonhuman primate model show that developmentally restricted SSEA-1(+) cardiac progenitors appear to be safe and highlight the benefit of the epicardial delivery of a construct harboring cells with a cardiomyogenic differentiation potential and cells providing them the necessary trophic support.


Asunto(s)
Tejido Adiposo/citología , Células Madre Embrionarias/trasplante , Infarto del Miocardio/terapia , Miocardio/patología , Regeneración , Trasplante de Células Madre/métodos , Tejido Adiposo/trasplante , Animales , Diferenciación Celular , Modelos Animales de Enfermedad , Humanos , Antígeno Lewis X , Macaca mulatta , Ratones , Miocitos Cardíacos/citología , Miocitos Cardíacos/metabolismo , Neovascularización Fisiológica , Células del Estroma , Trasplante Autólogo , Trasplante Homólogo
2.
Transplantation ; 83(3): 333-5, 2007 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-17297408

RESUMEN

To test the purported immune privilege of embryonic stem cells (ESC) in the challenging setting of xenotransplantation, 14 immunocompetent baboons were subjected to a coronary artery occlusion-reperfusion sequence and, two weeks later, randomized to receive in-scar injections of culture medium or cardiac-committed mouse ESC engineered to express fluorescent reporter genes driven by cardiac-specific promoters. Two months after transplantation, left ventricular function, as assessed by echocardiography, deteriorated to a similar extent in control and treated baboons. This correlated with failure to identify the grafted cells by X-gal histology and immunofluorescence. Rejection did not seem to be mediated by xenoantibodies, but rather by T lymphocytes and natural killer cells as suggested by positive immunostaining for CD3 and CD56 early after transplantation. There was no increase in circulating levels of regulatory T cells. These data raise a cautionary note about the immune privilege of ESC and suggest that from a mere immunologic standpoint, ESC xenotransplantation is likely to be an unrealistic challenge.


Asunto(s)
Células Madre Embrionarias/inmunología , Células Madre Embrionarias/trasplante , Rechazo de Injerto/inmunología , Infarto del Miocardio/cirugía , Trasplante Heterólogo/inmunología , Animales , Antígeno CD56/análisis , Electrocardiografía , Células Asesinas Naturales/inmunología , Ratones , Papio , Linfocitos T Reguladores/inmunología , Disfunción Ventricular Izquierda/diagnóstico
3.
Presse Med ; 35(6 Pt 2): 1081-7, 2006 Jun.
Artículo en Francés | MEDLINE | ID: mdl-16783277

RESUMEN

Regular physical activity is especially appropriate for hypertensive patients. Although its effect on individual blood pressure may be modest, its benefits at a population level are substantial. It is a method of choice for preventing hypertension. The levels of activity to be recommended remain uncertain, but intensive workouts are not required. Thirty minutes of brisk walking daily is beneficial. Benefits are not limited to blood pressure. Physical activity provides cardiovascular protection by reducing risk factors such as overweight and metabolic abnormalities. It also improves endothelial function, platelet activation and inflammatory response. More than simple physical exercise, we must promote the inclusion of healthy behavior into daily routines.


Asunto(s)
Hipertensión/prevención & control , Actividad Motora , Guías como Asunto , Humanos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda